CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Revenues:
License and milestone fees	$ 79	$ 76	$ 49,889	$ 10,229
Non-cash royalty revenue related to the sale of future royalties	6,503	6,184	20,555	19,508
Research and development support	650	1,354	3,030	3,748
Clinical materials revenue	1,248	46	2,525	1,297
Total revenues	8,480	7,660	75,999	34,782
Operating Expenses:
Research and development	31,689	32,909	99,896	107,655
General and administrative	7,908	9,459	24,863	29,992
Restructuring charges		4,130	386	4,130
Total operating expenses	39,597	46,498	125,145	141,777
Loss from operations	(31,117)	(38,838)	(49,146)	(106,995)
Investment income, net	293	146	551	360
Non-cash interest expense on liability related to the sale of future royalties and convertible senior notes	(3,385)	(5,018)	(10,461)	(14,946)
Interest expense on convertible senior notes	(762)	(1,150)	(3,012)	(1,288)
Non-cash debt conversion expense	(22,191)		(22,191)
Other income, net	480	129	1,365	288
Net loss	$ (56,682)	$ (44,731)	$ (82,894)	$ (122,581)
Basic and diluted net loss per common share (in dollar per share)	$ (0.61)	$ (0.51)	$ (0.93)	$ (1.41)
Basic and diluted weighted average common shares outstanding (in shares)	93,001	87,102	89,133	87,029
Total comprehensive loss	$ (56,682)	$ (44,731)	$ (82,894)	$ (122,581)